Sandoz confirms roadmap and highlight pipeline catalysts at J.P. Morgan Healthcare Conference
- Co will confirm its strategic roadmap and highlight pipeline catalysts in a presentation
- Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilars
- Leading in home market Europe, which represents half of total sales; strategically positioning company to become #1 in biosimilars in US, with three US launches expected in 2025
- Ambitious GLP-1 strategy in place, addressing each opportunity with mix of internal capabilities and external partnerships
- Industry-leading pipeline for rapidly-growing biosimilar segment now comprises 28 molecules
- Strongly positioned to capitalize on unprecedented global market opportunity, with reference medicines worth more than USD 400 billion in sales due to lose exclusivity from 2029 onwards